Allworth Financial’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Allworth Financial’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$417	Hold	10	–	–	﹤0.01%	4778
2025 Q4	$386	Hold	10	–	–	﹤0.01%	4585
2025 Q3	$273	Hold	10	–	–	﹤0.01%	4560
2025 Q2	$194	Hold	10	–	–	﹤0.01%	4319
2025 Q1	$187	Hold	10	–	–	﹤0.01%	3883
2024 Q4	$229	Hold	10	–	–	﹤0.01%	3760
2024 Q3	$280	Hold	10	–	–	﹤0.01%	3534
2024 Q2	$278	Hold	10	–	–	﹤0.01%	3504
2024 Q1	$292	Hold	10	–	–	﹤0.01%	3401
2023 Q4	$245	Hold	10	–	–	﹤0.01%	3263
2023 Q3	$197	Hold	10	–	–	﹤0.01%	3236
2023 Q2	$240	Hold	10	–	–	﹤0.01%	3061
2023 Q1	$220	Hold	10	–	–	﹤0.01%	2993
2022 Q4	$250	Buy	+10	New	+$249	﹤0.01%	2752

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $454M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $158M AUM

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Allworth Financial's BBC Position: Q1 2026 in Review

Allworth Financial held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q1 2026 at 10 shares worth $417. The position accounts for ﹤0.01% of the portfolio, ranked #4778.

Allworth Financial first reported a position in BBC in Q4 2022 and has held it in 14 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

Allworth Financial held 10 shares of Virtus Biotech Clinical Trials ETF worth $417 as of Q1 2026.
Allworth Financial left its Virtus Biotech Clinical Trials ETF share count unchanged in Q1 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4778 holding.
Allworth Financial first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2022 and has held it in 14 quarters since.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.